Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited has secured new funding of A$2.1 million from sophisticated investors and signed a Material Transfer Agreement with an overseas company, highlighting growing interest in its Sofra™ technology platform. The company is set to launch its first clinical trial for the autoimmune drug SOF-SKN™ in 2025, marking a pivotal step in its strategy to tap into the lucrative autoimmune disease market. Additionally, Noxopharm is expanding its oncology pipeline with promising research data on pancreatic cancer and glioblastoma.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
